Vicky Goh

Last updated

Vicky Goh is a professor, chair of clinical cancer imaging, and head of cancer imaging department [1] at the King's College London, England, United Kingdom. She joined King's College London in 2011. She is also a consultant radiologist at Guy's and St Thomas' Hospital in London. [2]

Contents

Biography

Goh studied at Cheltenham Ladies' College, obtained a medical degree from University of Cambridge. She further trained at General Medicine and Radiology in London (UK) and University Health Network Hospitals in Toronto (Canada). [3] She has also worked as a Consultant Oncological Radiologist at Mount Vernon Hospital in the area of colorectal cancer. [4] She served as a president of the European Society of Oncologic Imaging in the past. [5] She is now a chair of the academic committee at the Royal College of Radiologists, and steering committee member of the European School of Radiology. [6]

She is interested in studying tumour heterogeneity, micro-environment, biomarker development in gastrointestinal, lung and renal cancers in humans using multi-modality functional imaging. [7] According to Scopus, she has published 209 scientific documents with 7233 citations, and an h-index of 45. [8] She has been mentioned on public online-blogs on several occasions for her cancer imaging work. [9] [10] [11] Her ORCID profile can be found here. [12]

Prof Goh is a deputy editor for the Radiology journal. [13]

Books edited

Chapters edited

Selected publications

She has authored numerous publications. However, the following publications have more than 300 citations:

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.

<span class="mw-page-title-main">Radiology</span> Branch of medicine

Radiology is the medical specialty that uses medical imaging to diagnose diseases and guide their treatment, within the bodies of humans and other animals. It began with radiography, but today it includes all imaging modalities, including those that use no ionizing electromagnetic radiation, as well as others that do, such as computed tomography (CT), fluoroscopy, and nuclear medicine including positron emission tomography (PET). Interventional radiology is the performance of usually minimally invasive medical procedures with the guidance of imaging technologies such as those mentioned above.

Fluorodeoxyglucose (<sup>18</sup>F) Chemical compound

[18F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18, also commonly called fluorodeoxyglucose and abbreviated [18F]FDG, 2-[18F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-deoxy-2-[18F]fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule.

<span class="mw-page-title-main">Neuroimaging</span> Set of techniques to measure and visualize aspects of the nervous system

Neuroimaging is the use of quantitative (computational) techniques to study the structure and function of the central nervous system, developed as an objective way of scientifically studying the healthy human brain in a non-invasive manner. Increasingly it is also being used for quantitative research studies of brain disease and psychiatric illness. Neuroimaging is highly multidisciplinary involving neuroscience, computer science, psychology and statistics, and is not a medical specialty. Neuroimaging is sometimes confused with neuroradiology.

<span class="mw-page-title-main">Omental cake</span> Medical condition

Omental cake is a radiologic sign indicative of an abnormally thickened greater omentum. It refers to infiltration of the normal omental structure by other types of soft-tissue or chronic inflammation resulting in a thickened, or cake-like appearance.

<span class="mw-page-title-main">18F-EF5</span> Chemical compound

EF5 is a nitroimidazole derivative used in oncology research. Due to its similarity in chemical structure to etanidazole, EF5 binds in cells displaying hypoxia.

Abass Alavi is an Iranian-American physician-scientist specializing in the field of molecular imaging, most notably in the imaging modality of positron emission tomography (PET). In August 1976, he was part of the team that performed the first human PET studies of the brain and whole body using the radiotracer [18F]Fluorodeoxyglucose (FDG). Alavi holds the position of Professor of Radiology and Neurology, as well as Director of Research Education in the Department of Radiology at the University of Pennsylvania. Over a career spanning five decades, he has amassed over 2,300 publications and 60,000 citations, earning an h-index of 125 and placing his publication record in the top percentile of scientists.

An imaging biomarker is a biologic feature, or biomarker detectable in an image. In medicine, an imaging biomarker is a feature of an image relevant to a patient's diagnosis. For example, a number of biomarkers are frequently used to determine risk of lung cancer. First, a simple lesion in the lung detected by X-ray, CT, or MRI can lead to the suspicion of a neoplasm. The lesion itself serves as a biomarker, but the minute details of the lesion serve as biomarkers as well, and can collectively be used to assess the risk of neoplasm. Some of the imaging biomarkers used in lung nodule assessment include size, spiculation, calcification, cavitation, location within the lung, rate of growth, and rate of metabolism. Each piece of information from the image represents a probability. Spiculation increases the probability of the lesion being cancer. A slow rate of growth indicates benignity. These variables can be added to the patient's history, physical exam, laboratory tests, and pathology to reach a proposed diagnosis. Imaging biomarkers can be measured using several techniques, such as CT, electroencephalography, magnetoencephalography, and MRI.

<span class="mw-page-title-main">Brain positron emission tomography</span> Form of positron emission tomography

Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.

<span class="mw-page-title-main">Positron emission mammography</span> Imaging procedure used to detect breast cancer

Positron emission mammography (PEM) is a nuclear medicine imaging modality used to detect or characterise breast cancer. Mammography typically refers to x-ray imaging of the breast, while PEM uses an injected positron emitting isotope and a dedicated scanner to locate breast tumors. Scintimammography is another nuclear medicine breast imaging technique, however it is performed using a gamma camera. Breasts can be imaged on standard whole-body PET scanners, however dedicated PEM scanners offer advantages including improved resolution.

<span class="mw-page-title-main">FMISO</span> Chemical compound

18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18.

Fluoroethyl-<small>L</small>-tyrosine (<sup>18</sup>F) Chemical compound

Fluoroethyl-l-tyrosine (18F) commonly known as [18F]FET, is a radiopharmaceutical tracer used in positron emission tomography (PET) imaging. This synthetic amino acid, labeled with the radioactive isotope fluorine-18, is a valuable radiopharmaceutical tracer for used in neuro-oncology for diagnosing, planning treatment, and following up on brain tumors such as gliomas. The tracer's ability to provide detailed metabolic imaging of tumors makes it an essential tool in the clinical management of brain cancer patients. Continued advancements in PET imaging technology and the development of more efficient synthesis methods are expected to further enhance the clinical utility of [18F]FET.

In the field of medicine, radiomics is a method that extracts a large number of features from medical images using data-characterisation algorithms. These features, termed radiomic features, have the potential to uncover tumoral patterns and characteristics that fail to be appreciated by the naked eye. The hypothesis of radiomics is that the distinctive imaging features between disease forms may be useful for predicting prognosis and therapeutic response for various cancer types, thus providing valuable information for personalized therapy. Radiomics emerged from the medical fields of radiology and oncology and is the most advanced in applications within these fields. However, the technique can be applied to any medical study where a pathological process can be imaged.

Fluciclovine (<sup>18</sup>F) Chemical compound

Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, and sold under the brand name Axumin, is a diagnostic agent used for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

<span class="mw-page-title-main">Andreas Kjær (scientist)</span> Danish physician-scientist

Andreas Kjær is a Danish physician-scientist and European Research Council (ERC) advanced grantee. He is professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. He is board certified in Nuclear Medicine and his research is focused on molecular imaging with PET and PET/MRI and targeted radionuclide therapies (theranostics) in cancer. His achievements include development of several new PET tracers that have reached first-in-human clinical use. He has published more than 400 peer-review articles, filed 10 patents, supervised more than 40 PhD students and received numerous prestigious scientific awards over the years. He is a member of the Danish Academy of Technical Sciences

Philip F. Cohen is a Canadian clinical director of Nuclear Medicine working out of the Lions Gate Hospital in North Vancouver, British Columbia. As a nuclear medicine physician, he is a pioneer in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Furthermore, Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, Cohen was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow.

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.

Jamshed Bomanji is a full professor, clinical lead, and head of the Institute of Nuclear medicine department at the University College Hospital (UCLH) NHS foundation trust based in London, UK.

Sally Barrington is a professor of positron emission tomography (PET) Imaging and National Institute for Health Research (NIHR) research professor at King's College London (KCL), England, United Kingdom. She joined KCL in 1993.

References

  1. ↑ "School leadership | School of Biomedical Engineering & Imaging Sciences | King's College London". www.kcl.ac.uk. Retrieved 2020-07-21.
  2. ↑ "Professor Vicky Goh". www.kcl.ac.uk. Retrieved 2020-07-21.
  3. ↑ "Vicky Goh - Hybrid". www.hybrid2020.eu. Retrieved 2020-07-21.
  4. ↑ "School leadership | School of Biomedical Engineering & Imaging Sciences | King's College London". www.kcl.ac.uk. Retrieved 2020-07-23.
  5. ↑ "Vicky Goh - Biography - Research Portal, King's College, London". kclpure.kcl.ac.uk. Retrieved 2020-07-23.
  6. ↑ "Vicky Goh - Biography - Research Portal, King's College, London". kclpure.kcl.ac.uk. Retrieved 2020-07-21.
  7. ↑ "King's College London - Professor Vicky Goh". www.kcl.ac.uk. Retrieved 2020-07-21.
  8. ↑ "Scopus preview - Scopus - Author details (Goh, Vicky)". www.scopus.com. Retrieved 2020-07-21.
  9. ↑ "New chest X-ray AI app could help relieve reporting backlog in the UK". dotmed.com. Retrieved 2020-07-21.
  10. ↑ "AI can assist in triaging abnormal chest X-rays". Physics World. 2019-02-04. Retrieved 2020-07-21.
  11. ↑ "Champagne and PET/MRI: Why they're so similar". AuntMinnieEurope.com. Retrieved 2020-07-21.
  12. ↑ ORCID. "Vicky Goh (0000-0002-2321-8091)". www.scopus.com. Retrieved 2020-07-21.
  13. ↑ "Radiology". pubs.rsna.org. Retrieved 2020-07-21.
  14. ↑ Hoskin, Peter J. Goh, Vicky. (2010). Radiotherapy in practice : imaging. Oxford University Press. ISBN   978-0-19-923132-4. OCLC   624427469.{{cite book}}: CS1 maint: multiple names: authors list (link)
  15. ↑ Grainger & Allison's diagnostic radiology. Oncological imaging. Goh, Vicky., Adam, Andy. (6th ed.). London: Elsevier. 2016. ISBN   978-0-7020-6935-2. OCLC   922460588.{{cite book}}: CS1 maint: others (link)
  16. ↑ Stoker, Jaap, ed. (2011). MRI of the gastrointestinal tract. Medical Radiology. Berlin Heidelberg: Springer. ISBN   978-3-642-23585-6. OCLC   1136157854.
  17. ↑ Nikolaou, Konstantin; Bamberg, Fabian; Laghi, Andrea; Rubin, Geoffrey D. (2019-08-06). Multislice CT. Springer. ISBN   978-3-319-42586-3.
  18. ↑ Gourtsoyianni, Sofia Herausgeber. Papanikolaou, Nikolaos Herausgeber. (15 October 2018). Diffusion Weighted Imaging of the Gastrointestinal Tract : Techniques and Clinical Applications. ISBN   978-3-319-92819-7. OCLC   1089713894.{{cite book}}: CS1 maint: multiple names: authors list (link)
  19. ↑ Iagaru, Andrei, Sonstige. Hope, Thomas, Sonstige. Veit-Haibach, Patrick, Sonstige. (23 January 2018). PET/MRI in Oncology : Current Clinical Applications. ISBN   978-3-319-68517-5. OCLC   1021387143.{{cite book}}: CS1 maint: multiple names: authors list (link)
  20. ↑ Hayat, M. A., 1940- (2009). Colorectal cancer. Springer. ISBN   978-1-4020-9544-3. OCLC   495283061.{{cite book}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  21. ↑ Davnall, Fergus; Yip, Connie S. P.; Ljungqvist, Gunnar; Selmi, Mariyah; Ng, Francesca; Sanghera, Bal; Ganeshan, Balaji; Miles, Kenneth A.; Cook, Gary J.; Goh, Vicky (2012-10-24). "Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?". Insights into Imaging. 3 (6): 573–589. doi:10.1007/s13244-012-0196-6. ISSN   1869-4101. PMC   3505569 . PMID   23093486. S2CID   27730.
  22. ↑ O'Connor, James P. B. Aboagye, Eric O. Adams, Judith E. Aerts, Hugo J. W. L. Barrington, Sally F. Beer, Ambros J. Boellaard, Ronald Bohndiek, Sarah E. Brady, Michael Brown, Gina Buckley, David L. Chenevert, Thomas L. Clarke, Laurence P. Collette, Sandra Cook, Gary J. Desouza, Nandita M. Dickson, John C. Dive, Caroline Evelhoch, Jeffrey L. Faivre-Finn, Corinne Gallagher, Ferdia A. Gilbert, Fiona J. Gillies, Robert J. Goh, Vicky Griffiths, J. R. Groves, Ashley M. Halligan, Steve Harris, Adrian L. Hawkes, David J. Hoekstra, Otto S. Huang, Erich P. Hutton, Brian F. Jackson, Edward F. Jayson, Gordon C. Jones, Andrew Koh, Dow-Mu Lacombe, Denis Lambin, Philippe Lassau, Nathalie Leach, Martin O. Lee, Ting-Yim Leen, Edward L. Lewis, Jason S. Liu, Yan Lythgoe, Mark F. Manoharan, Prakash Maxwell, Ross J. Miles, Kenneth A. Morgan, Bruno Morris, Steve Ng, Tony Padhani, Anwar R. Parker, Geoff J. M. Partridge, Mike Pathak, Arvind P. Peet, Andrew C. Punwani, Shonit Reynolds, Andrew R. Robinson, Simon P. Shankar, Lalitha K. Sharma, Ricky A. Soloviev, Dmitry Stroobants, Sigrid G. Sullivan, Daniel C. Taylor, Stuart A. Tofts, Paul S. Tozer, Gillian M. van Herk, Marcel B. Walker-Samuel, Simon Wason, James Williams, Kaye J. Workman, Paul Yankeelov, Thomas E. Brindle, Kevin M. McShane, Lisa M. Jackson, Alan Waterton, John C. (March 2017). Imaging biomarker roadmap for cancer studies. OCLC   1000469274.{{cite book}}: CS1 maint: multiple names: authors list (link)
  23. ↑ Imperial College London; University of Dundee; University of Southampton; University of Birmingham; University of Manchester; University of Sheffield; King's College London; University College London; Cancer Research UK/University of Cambridge; Newcastle University; University of Nottingham; London School of Hygiene and Tropical Medicine; Queen Mary University of London; University of Glasgow; University of East Anglia; University College Dublin; The Institute of Cancer Research; University of Cardiff; University of Leeds; Royal College of Surgeons Ireland; University of Chester; University of Oxford; University of Edinburgh; National Cancer Research Institute; Queen’s University Belfast; University College Cork; University of Leicester; Princess Alice Hospice; University of Sussex; University of Liverpool; London Research Institute; Brunel University; Cambridge University Hospitals NHS Eccles, Suzanne A. Aboagye, Eric O. Ali, Simak Anderson, Annie S. Armes, Jo Berditchevski, Fedor Blaydes, Jeremy P. Brennan, Keith Brown, Nicola J. Bryant, Helen E. Bundred, Nigel J. Burchell, Joy M. Campbell, Anna M. Carroll, Jason S. Clarke, Robert B. Coles, Charlotte E. Cook, Gary J. Cox, Angela Curtin, Nicola J. Dekker, Lodewijk V. dos Santos Silva, Isabel Duffy, Stephen W. Easton, Douglas F. Eccles, Diana M. Edwards, Dylan R. Edwards, Joanne Evans, D. Gareth Fenlon, Deborah F. Flanagan, James M. Foster, Claire Gallagher, William M. Garcia-Closas, Montserrat Gee, Julia M. W. Gescher, Andy J. Goh, Vicky Groves, Ashley M. Harvey, Amanda J. Harvie, Michelle Hennessy, Bryan T. Hiscox, Stephen Holen, Ingunn Howell, Sacha J. Howell, Anthony Hubbard, Gill Hulbert-Williams, Nicholas J. Hunter, Myra S. Jasani, Bharat Jones, Louise J. Key, Timothy J. Kirwan, Cliona C. Kong, Anthony Kunkler, Ian H. Langdon, Simon P. Leach, Martin O. Mann, David J. Marshall, John F. Martin, Lesley A. Martin, Stewart G. Macdougall, Jennifer E. Miles, David W. Miller, William R. Morris, Joanna R. Moss, Sue M. Mullan, Paul Natrajan, Rachel O’Connor, James P. O’Connor, Rosemary Palmieri, Carlo Pharoah, Paul D. P. Rakha, Emad A. Reed, Elizabeth Robinson, Simon P. Sahai, Erik Saxton, John M. Schmid, Peter Smalley, Matthew J. Speirs, Valerie Stein, Robert Stingl, John Streuli, Charles H. Tutt, Andrew N. J. Velikova, Galina Walker, Rosemary A. Watson, Christine J. Williams, Kaye J. Young, Leonie S. Thompson, Alastair M. (2013-10-01). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. BioMed Central. OCLC   946781660.{{cite book}}: CS1 maint: multiple names: authors list (link)
  24. ↑ Chicklore, Sugama; Goh, Vicky; Siddique, Musib; Roy, Arunabha; Marsden, Paul K.; Cook, Gary J. R. (2012-10-13). "Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis". European Journal of Nuclear Medicine and Molecular Imaging. 40 (1): 133–140. doi:10.1007/s00259-012-2247-0. ISSN   1619-7070. PMID   23064544. S2CID   24695383.
  25. ↑ Glynne-Jones, Robert; Nilsson, Per; Aschele, Carlo; Goh, Vicky; Peiffert, Didier; Cervantes, Andres; Arnold, Dirk (2014). "Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up". Radiotherapy and Oncology. 111 (3): 330–9. doi: 10.1016/j.radonc.2014.04.013 . PMID   24947004.
  26. ↑ Cook, G. J. R.; Yip, C.; Siddique, M.; Goh, V.; Chicklore, S.; Roy, A.; Marsden, P.; Ahmad, S.; Landau, D. (2012-11-30). "Are Pretreatment 18F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?". Journal of Nuclear Medicine. 54 (1): 19–26. doi: 10.2967/jnumed.112.107375 . ISSN   0161-5505. PMID   23204495. S2CID   3122995.
  27. ↑ Ng, Francesca; Ganeshan, Balaji; Kozarski, Robert; Miles, Kenneth A.; Goh, Vicky (2013). "Assessment of Primary Colorectal Cancer Heterogeneity by Using Whole-Tumor Texture Analysis: Contrast-enhanced CT Texture as a Biomarker of 5-year Survival". Radiology. 266 (1): 177–184. doi: 10.1148/radiol.12120254 . hdl: 2299/9802 . ISSN   0033-8419. PMID   23151829.
  28. ↑ Ganeshan, Balaji; Goh, Vicky; Mandeville, Henry C.; Ng, Quan Sing; Hoskin, Peter J.; Miles, Kenneth A. (2013). "Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT". Radiology. 266 (1): 326–336. doi: 10.1148/radiol.12112428 . ISSN   0033-8419. PMID   23169792.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.